

BY: Delegate Redmer

AMENDMENTS TO SENATE BILL NO. 623, AS AMENDED

AMENDMENT NO. 1

On page 1 of the Environmental Matters Committee Amendments (SB0623/580915/1), in line 4 of Amendment No. 1, after “rebates;” insert “providing for the effect of the Department’s negotiating of or failure to negotiate a supplemental rebate with a manufacturer;”.”

AMENDMENT NO. 2

On page 2 of the Environmental Matters Committee Amendments, in line 6 of Amendment No. 3, after “(D)” insert “(1)”; in line 7, after “MPAP.” insert:

“(2) (I) THE DEPARTMENT’S NEGOTIATION OF A SUPPLEMENTAL REBATE WITH A MANUFACTURER OR FAILURE TO NEGOTIATE A SUPPLEMENTAL REBATE MAY NOT BE A FACTOR IN THE CONSIDERATION OF A MANUFACTURER’S PRODUCT FOR INCLUSION ON THE PREFERRED DRUGS LIST; AND

(II) A MANUFACTURER’S PRODUCT MAY NOT BE EXCLUDED FROM THE PREFERRED DRUG LIST BECAUSE A MANUFACTURER FAILED TO NEGOTIATE A SUPPLEMENTAL REBATE.”